import Link from "next/link"
import type { BlogPostMeta } from "@/lib/blog/types"
import {
  H2,
  H3,
  P,
  Lead,
  UL,
  LI,
  Strong,
  Callout,
  BeforeAfter,
  KeyTakeaways,
} from "@/components/blog/prose"

export const meta: BlogPostMeta = {
  slug: "glp-1-compounded-marketing-compliance-2026",
  title:
    "Compounded GLP-1 Marketing Compliance in 2026: What Changed When the Shortage List Closed",
  description:
    "Compounded semaglutide and tirzepatide marketing in 2026 sits in a different regulatory posture than it did during the 2023-2024 shortage years. Here is what changed, what the FDA has actually said, and how to position a compounded GLP-1 program without inviting a warning letter.",
  excerpt:
    "When the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for routine 503A compounding narrowed. Your existing compounded-GLP-1 marketing was probably written for the old posture. Here is the 2026 rewrite.",
  date: "2026-05-19",
  readingMinutes: 9,
  keywords: [
    "GLP-1 compounded marketing compliance",
    "compounded semaglutide advertising 2026",
    "tirzepatide compounding shortage list",
    "503A compounded GLP-1 rules",
    "FDA compounded semaglutide enforcement",
  ],
  tags: ["GLP-1", "Compounding", "Weight loss", "Specialty playbook"],
  author: { name: "RegenCompliance Editorial", role: "FDA/FTC compliance desk" },
  heroLabel: "Modality playbook",
}

export default function Body() {
  return (
    <>
      <Lead>
        Compounded GLP-1 marketing was easier to defend during the 2023-2024
        shortage years than it is in 2026. When the FDA resolved the
        semaglutide and tirzepatide shortages and signaled the end of the
        broad shortage-based compounding window, the legal posture under
        which most clinics were marketing compounded GLP-1 quietly shifted.
        A lot of clinic copy is still written for the old rules.
      </Lead>

      <P>
        This post walks through the 2026 reality for compounded GLP-1
        advertising: what the FDA actually said, what counts as a defensible
        compounding rationale now, the claim patterns that survived the
        shift, and the ones that did not. It is the companion to our broader{" "}
        <Link
          href="/blog/glp-1-semaglutide-marketing-compliance"
          className="text-[#55E039] font-semibold hover:underline underline-offset-2"
        >
          GLP-1 marketing compliance overview
        </Link>{" "}
        and is focused tightly on the compounded-product layer.
      </P>

      <Callout variant="warn" title="The 2026 shift, in one sentence">
        Marketing copy that leaned on shortage-list status to justify broad
        compounding of semaglutide or tirzepatide is operating on an
        expired premise; clinics that did not refresh their compounding
        rationale, prescriber documentation, and patient-facing language
        are exposed to a kind of FDA action that was unlikely under the
        shortage framework.
      </Callout>

      <H2 id="what-changed">What the FDA actually changed</H2>
      <P>
        Two pieces of public FDA action matter here. First, the FDA
        resolved the semaglutide and tirzepatide drug-shortage listings,
        which removed the broad statutory basis that 503A and 503B
        compounders had been using to produce these molecules at scale.
        Second, the agency has continued to issue warning letters and
        public communications targeting compounded GLP-1 marketing
        patterns that present compounded products as interchangeable with
        FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound.
      </P>
      <P>
        Compounding of these drugs is not extinct. Patient-specific
        compounding under section 503A remains permissible where there is
        a documented clinical reason a commercially available product
        will not work for the individual patient. What is gone is the
        permission slip the shortage list provided for routine,
        marketed-to-the-public compounded GLP-1 programs.
      </P>

      <H2 id="patterns-flagged">Marketing patterns the FDA has flagged</H2>
      <UL>
        <LI>
          <Strong>Brand-name implication.</Strong> Copy that uses Wegovy,
          Ozempic, Mounjaro, or Zepbound to draw a prospect in, then sells
          a compounded product, is treated as misbranding-adjacent. The
          warning-letter pattern over the last 24 months is consistent on
          this point.
        </LI>
        <LI>
          <Strong>Equivalence claims.</Strong> Same-as-Ozempic, generic-
          version-of-Wegovy, and FDA-approved-active-ingredient phrasings
          imply the compounded product itself has FDA approval. A molecule
          and a finished drug product are not the same thing.
        </LI>
        <LI>
          <Strong>Open-market positioning.</Strong> Compounding under
          section 503A is patient-specific. Advertising compounded
          semaglutide directly to the general public, with online ordering
          and no patient-specific clinical rationale visible, looks like
          manufacturing-by-another-name.
        </LI>
        <LI>
          <Strong>Outcome guarantees.</Strong> A guarantee of 20 lbs in
          60 days on a compounded product compounds the problem. See
          section 5 of the FTC Act on outcome substantiation; FTC has
          taken weight-loss outcome claims as a settled enforcement
          priority since the Pom Wonderful era.
        </LI>
        <LI>
          <Strong>Telehealth-funnel disclaimers buried in footers.</Strong>{" "}
          If the disclosure that a patient is being prescribed a
          compounded product distinct from the FDA-approved drug only
          appears in 10pt grey type at the bottom of the page, the
          disclosure has not actually been made for FTC clear-and-
          conspicuous purposes.
        </LI>
      </UL>

      <H2 id="rewrite-rules">Three rewrite rules for 2026</H2>
      <H3>1. Lead with what you actually dispense, by molecule</H3>
      <BeforeAfter
        bad="Affordable Wegovy alternative - $299/mo with no insurance hassle."
        good="Medically supervised weight management program using semaglutide compounded for the individual patient at a state-licensed compounding pharmacy. This is not FDA-approved Wegovy or Ozempic; eligibility is determined during clinical consultation."
        reason="Lead with the molecule and the compounding pathway, not the brand-name halo. The non-FDA-approved disclosure is not buried at the bottom; it is in the lead."
      />

      <H3>2. Make the patient-specific rationale visible</H3>
      <BeforeAfter
        bad="Order compounded semaglutide online today - approval in minutes, shipped in 48 hours."
        good="Each patient completes a clinical intake reviewed by a licensed prescriber, who decides whether a compounded GLP-1 is clinically appropriate and writes a patient-specific prescription. Compounded preparations are not interchangeable with FDA-approved drug products."
        reason="The on-demand, no-friction frame is the exact pattern FDA cites when challenging whether a 503A operation is acting as a de facto manufacturer."
      />

      <H3>3. Quote substantiation by name, or do not quote it</H3>
      <BeforeAfter
        bad="Studies show our compounded GLP-1 helps patients lose up to 20% of body weight."
        good="In a 2021 New England Journal of Medicine trial of FDA-approved semaglutide 2.4 mg for chronic weight management (Wilding et al., STEP 1), participants meeting BMI eligibility criteria experienced an average weight reduction over 68 weeks. Individual outcomes on compounded preparations are not the same data set and will vary."
        reason="The Pom Wonderful FTC standard requires that cited evidence actually support the specific product claim. Borrowing branded-drug clinical trial data to support a compounded product overclaims; if you cite a trial, you have to name it and qualify it."
      />

      <H2 id="program-page-checklist">Program page checklist</H2>
      <UL>
        <LI>Lead headline names the molecule, not the brand.</LI>
        <LI>
          A how-this-program-works section describes the consultation,
          eligibility screening, prescription basis, and follow-up cadence.
        </LI>
        <LI>
          A what-you-are-getting section explicitly states the product
          is compounded, by whom, and clarifies that it is not FDA-approved
          Wegovy or Ozempic.
        </LI>
        <LI>
          Any cited clinical evidence is named (study, year, journal) and
          the population/duration is disclosed.
        </LI>
        <LI>
          Outcomes language describes ranges from named trials, not
          guarantees, and includes a clear individual-variation
          disclosure.
        </LI>
        <LI>
          Risk and side-effect information is present and accessible, not
          hidden behind an expand-on-click element on mobile.
        </LI>
      </UL>

      <Callout variant="success" title="Compounded GLP-1 rules in the scanner">
        <span>
          RegenCompliance includes 2026-updated GLP-1 rules covering
          brand-name implication, post-shortage compounding rationale,
          equivalence claims, and outcome substantiation. If you run a
          compounded GLP-1 program, pre-publish scanning will flag the
          patterns above before a regulator or platform does.{" "}
          <Link
            href="/apply"
            className="text-[#55E039] font-semibold hover:underline underline-offset-2"
          >
            Apply for the founder beta
          </Link>{" "}
          or review what we cover on the{" "}
          <Link
            href="/coverage"
            className="text-[#55E039] font-semibold hover:underline underline-offset-2"
          >
            modality coverage page
          </Link>
          .
        </span>
      </Callout>

      <H2 id="related-modalities">Adjacent rules to know</H2>
      <P>
        Many compounded GLP-1 programs sit inside a broader men&rsquo;s
        health or hormone clinic that also offers testosterone services.
        The marketing rules for{" "}
        <Link
          href="/blog/trt-marketing-compliance-mens-health"
          className="text-[#55E039] font-semibold hover:underline underline-offset-2"
        >
          TRT for men&rsquo;s health
        </Link>{" "}
        share several patterns with compounded GLP-1 work, particularly
        around outcome substantiation and on-demand prescribing optics.
      </P>

      <KeyTakeaways
        items={[
          "The FDA-declared end of the semaglutide and tirzepatide shortages narrowed the legal basis for routine compounding; broad shortage-based marketing copy is now stale.",
          "Patient-specific 503A compounding remains permissible where the clinical record supports it; mass-market open enrollment for compounded GLP-1 does not.",
          "Brand-name implication, equivalence framing, on-demand telehealth optics, and outcome guarantees are the four patterns FDA and FTC actions have consistently flagged.",
          "Lead with the molecule, surface the patient-specific rationale, and cite trial evidence by name with population and duration disclosed.",
          "Move clear-and-conspicuous compounded-vs-approved disclosures into the lead, not footnotes - that is what FTC clear-and-conspicuous means in practice.",
        ]}
      />
    </>
  )
}
